Apexelsin 5 mg/ml powder for dispersion for infusion.
Sponsors
Centre Hospitalier Universitaire Rouen, Fondation Franc.Cancerologie Digestive
Conditions
Resectable borderline pancreatic adenocarcinomaresected pancreatic adenocarcinoma
Phase 2
Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with FOLFIRINOX
FRENCH26 – PRODIGE93 - PANACHE02 Trial
RecruitingCTIS2024-519048-33-00
Start: 2025-11-25Target: 390Updated: 2025-05-28
PRODIGE 104 – NEOPREDICT
A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.
Not yet recruitingCTIS2024-519753-11-00
Target: 110Updated: 2025-10-17